Skip to main content
Premium Trial:

Request an Annual Quote

N-of-One Inks Deal With NeoGenomics to Interpret Cancer Dx Tests

NEW YORK (GenomeWeb) – Bioinformatics firm N-of-One today announced an agreement with NeoGenomics to interpret the results of tests performed by the cancer genetics diagnostics firm.

Under the agreement, Lexington, Mass.-based N-of-One will provide clinical and interpretive evidence for NeoGenomics' NeoType solid tumor NGS tests, which report the most common and actionable genomic abnormalities in various subtypes of solid tumors.

Financial terms of the agreement were not disclosed.

"NeoGenomics selected N-of-One because of their oncology domain expertise and the flexible and efficient approach to tailoring their interpretation to meet our needs," NeoGenomics Chief Medical Officer Maher Albitar of said in a statement.

Fort Meyers, Fla.-based NeoGenomics is a high-complexity CLIA-certified clinical laboratory that provides a series of cancer testing services, including cytogenetics, FISH, flow cytometry, immunohistochemistry, and molecular genetic testing.

N-of-One provides highly scalable, cost-effective, patient-specific clinical interpretation for oncology testing.